Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.40 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.33 |
| ▸ | MAOA | P21397 | 3/20 | 0.32 |
| ▸ | MAOB | P27338 | 3/20 | 0.32 |
| ▸ | TOP1 | P11387 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4310948 | 1.00 | NTRK1 (0.40) | NTRK1CCNA2CDK2CCNA1KCNJ1 | |
| SCHEMBL4312957 | 0.92 | NTRK1 (0.37) | NTRK1CCNA2CDK2CCNA1KCNH2 | |
| SCHEMBL4312954 | 0.92 | NTRK1 (0.37) | NTRK1CCNA2CDK2CCNA1KCNH2 | |
| SCHEMBL4313015 | 0.92 | NTRK1 (0.43) | NTRK1CCNA2CDK2CCNA1KCNJ1 | |
| SCHEMBL4313011 | 0.92 | NTRK1 (0.43) | NTRK1CCNA2CDK2CCNA1KCNJ1 | |
| SCHEMBL4303529 | 0.91 | KDR (0.37) | NTRK1CCNA2CDK2CCNA1KCNJ1 | |
| SCHEMBL4303526 | 0.91 | KDR (0.37) | NTRK1CCNA2CDK2CCNA1KCNJ1 | |
| SCHEMBL4316843 | 0.91 | NTRK1 (0.38) | NTRK1CCNA2CDK2CCNA1KCNJ1 | |
| SCHEMBL4316845 | 0.91 | NTRK1 (0.38) | NTRK1CCNA2CDK2CCNA1KCNJ1 | |
| SCHEMBL4307441 | 0.88 | KDR (0.38) | KCNJ1KCNH2ABCB1TOP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130267497-A1 | KINASE INHIBITORS | ALLERGAN INC (US) | 2013-10-10 | — | — | US | disclosed |
| US-8455656-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20120238558-A9 | Kinase inhibitors | ALLERGAN, INC. | 2012-09-20 | — | — | US | disclosed |
| US-20090286773-A1 | Kinase inhibitors | ALLERGAN, INC. | 2009-11-19 | — | — | US | disclosed |
| US-20060004084-A1 | (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267497-A1 | KINASE INHIBITORS | PTK2, MAP3K6, MAP3K20 | NTRK1 307/4885CCNA2 695/4885CDK2 78/4885 |
| US-20090286773-A1 | Kinase inhibitors | PTK2, MAP3K6, MAP3K20 | NTRK1 307/4885CCNA2 695/4885CDK2 78/4885 |
| US-20060004084-A1 | (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | CDK2, ERBB2, MAP3K3 | NTRK1 408/4885CCNA2 406/4885CDK2 1/4885 |
| US-20120238558-A9 | Kinase inhibitors | PTK2, MAP3K6, MAP3K20 | NTRK1 307/4885CCNA2 695/4885CDK2 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.